管理类风湿性关节炎的不同方式:从A到Z的故事
Mohamed Ahmed Raslan1, Sara Ahmed Raslan1, Eslam Mansour Shehata1
1Drug Research Center, P.O. Box 11799, Cairo, Egypt.
Future science OA
|June 3, 2024
概括
早期的类风湿性关节炎 (RA) 治疗至关重要. 改变疾病的抗风湿药物和特定的饮食模式显示出对有效和安全地管理RA的希望.
科学领域:
- 风湿病学和免疫学
- 药理学和治疗学 药理学和治疗学
- 营养科学 营养科学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特点是关节炎症和可能导致渐进的关节损伤.
- 目前的治疗策略旨在控制疾病活动,预防结构损伤,改善患者的生活质量.
- 需要改进的治疗方法,提高疗效和安全性,仍然是RA管理的一个关键挑战.
研究的目的:
- 探索各种类风湿性关节炎 (RA) 的治疗策略,目的是优化治疗疗效.
- 确定治疗方式,为RA患者提供改善的安全概况.
- 研究生活方式因素,包括饮食在类风湿性关节炎管理中的作用.
主要方法:
- 使用医学科目标题 (MeSH) 进行了系统的文献搜索,以确定相关研究.
- 研究选择是根据预定义的包含和排除标准进行的,以确保数据的相关性.
- 分析重点关注治疗结果,安全数据以及抗炎和抗氧化化合物的影响.
主要成果:
- 在RA早期干预对于有效控制疾病和预防功能衰退至关重要.
- 改变疾病的抗风湿药物 (DMARDs) 代表了RA治疗的重大进步,提供了有前途的结果.
- 某些食物具有抗炎和抗氧化特性,可以防止RA的发展和进展.
结论:
- 一个个性化的管理计划,根据个体患者数据进行信息化,对于提高RA患者的生活质量至关重要.
- 药物治疗 (例如,DMARDs) 与潜在有益的饮食干预措施的整合可能为RA管理提供一种全面的方法.
- 对量身定制的治疗策略进行进一步的研究是有必要的,以改善类风湿性关节炎患者的长期结果.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Autoimmune Disorders
417
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
417
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421


